Oral Lichen Planus Clinical Trial
Official title:
Salivary and Serum Leptin Levels in Oral Lichen Planus Patients: A Case-Control Study.
This study aims to evaluate the levels of leptin in both saliva and serum samples of patients diagnosed with oral lichen.
Oral lichen planus is a frequently encountered chronic muco-cutaneous condition with a high prevalence rate. The condition can be classified as an autoimmune disorder.Although the exact cause of this condition is unknown, some potential risk factors should be taken into account, such as systemic disorders, psychogenic diseases, dental restorations, and certain medications. The oral lesions exhibit a mostly bilateral pattern, often manifesting in the inner buccal mucosa. The condition can be classified into three distinct forms, namely the reticular form, atrophic form, and bullous-erosive form. The condition is classified as a premalignant lesion due to its significant likelihood of undergoing malignant transformation. The disease is characterized by the presence of T-lymphocyte infiltration in the basal cell layer of the epithelium and the presence of cytoid bodies, which are distinct histopathologic markers. Leptin, a hormone generated by adipocytes, is involved in immunological responses and contributes to the development of autoimmunity. The presence of dyslipidemia has been found to be associated with lipoprotein (LP) abnormalities. Consequently, this study was undertaken to assess the blood leptin levels and lipid profile in individuals with LP. Leptin, a polypeptide hormone, is produced and released by white adipose tissue. Multiple research have substantiated an increase in leptin levels among persons exhibiting elevated body mass index (BMI) and a higher percentage of total body fat. Additionally, it is involved in the cellular immune response and facilitates the development of autoimmunity. There is a proposition suggesting that leptin has a role in the promotion of cytokine generation and modulation of helper T cells, potentially implicating its involvement in the pathogenesis of psoriasis. The available information about leptin status in dermatological illnesses other than psoriasis is currently sparse. It is plausible that it may have a significant role in the pathogenesis of lichen planus. However, there is a lack of literature regarding the levels of leptin in LP. There is an association between dyslipidemia and LP. Numerous investigations have consistently demonstrated notable deviations in lipid profile levels between individuals with LP and those in normal, healthy control cohorts. These findings have led researchers to posit a correlation between chronic inflammation and dyslipidemia, hence heightening the susceptibility to cardiovascular illnesses. The potential impact of leptin on the progression of LP is being investigated. The objective of this study was to conduct a comparative analysis of blood leptin levels between individuals recently diagnosed with LP and a control group consisting of healthy individuals. Additionally, an assessment was conducted to examine the correlation between leptin levels, lipid profile, and the length of illness. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05997173 -
The Regulatory Role of Immune Response in Oral Lichen Planus
|
||
| Completed |
NCT02443311 -
Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus
|
Phase 4 | |
| Completed |
NCT00484250 -
Study of Metronidazole and Doxycycline to Treat Oral Lichen Planus and to Compare Their Efficacy With Each Other
|
Phase 2 | |
| Completed |
NCT03682562 -
Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
|
||
| Completed |
NCT04193748 -
Evaluation of Topical Pomegranate Extracts in Management of Oral Lichen Planus (A Randomized Clinical Trial)
|
Phase 4 | |
| Completed |
NCT04153266 -
Oral Epithelial Dysplasia Informational Needs Questionnaire
|
||
| Recruiting |
NCT06135805 -
Impact of Fluocinonide 0,05% in Oral Lichen Planus
|
N/A | |
| Completed |
NCT04289233 -
Molecular & Cellular Characterisation of Oral Lichen Planus
|
||
| Completed |
NCT04293718 -
Acquired Chronic Erosive Gingivitis: Clinical Relevance of Papillary Gingival Biopsy
|
||
| Completed |
NCT00525421 -
A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus
|
Phase 2 | |
| Not yet recruiting |
NCT04091698 -
Clinical and Biochemical Assessment of the Effect of Topical Use of Coenzyme Q10 Versus Topical Corticosteroid in Management of Symptomatic Oral Lichen Planus: Randomized Controlled Clinical Trial
|
Phase 1 | |
| Completed |
NCT03386643 -
Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus
|
Phase 2 | |
| Withdrawn |
NCT03836885 -
Apremilast - Oral Lichen Planus Trial
|
Phase 2 | |
| Completed |
NCT05730855 -
Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions
|
||
| Completed |
NCT03257228 -
The Association Between Diabetes Mellitus, Oral Lichen Planus and Insulin-like Growth Factors 1 and 2 (IGF1 and IGF2)
|
N/A | |
| Recruiting |
NCT03026478 -
Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus
|
Phase 2 | |
| Completed |
NCT02858297 -
Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus
|
Phase 4 | |
| Completed |
NCT02834520 -
Expression of miRNa-138 and Cyclin D1 in Oral Mucosa of Patients With Oral Lichen Planus
|
N/A | |
| Completed |
NCT02106468 -
The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus
|
Phase 2 | |
| Recruiting |
NCT00737854 -
Free Soft Tissue Graft in Treatment of Oral Lichen Planus
|
Phase 1 |